Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer

被引:29
|
作者
Julien, Daniel C. [1 ]
Behnke, Steven [1 ]
Wang, Guankui [1 ]
Murdoch, Gordon K. [1 ]
Hill, Rodney A. [1 ]
机构
[1] Univ Idaho, Dept Anim & Vet Sci, Moscow, ID 83843 USA
基金
美国国家科学基金会;
关键词
cancer; immunotherapy; nanomaterial; nanomedicine;
D O I
10.4161/mabs.3.5.16089
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Due to their excellent specificity for a single epitope, monoclonal antibodies (mAbs) present a means of influencing the function of cells at the molecular level. In particular they show great promise in the treatment of cancer because they can inhibit cancer cell proliferation, tumor angiogenesis, invasiveness and malignant spread of cancerous cells. Many mAbs are in various stages of testing and 11 are currently marketed in the US or Europe for the treatment of cancers that express particular antigens such as human epidermal growth factor receptor-2, CD20, epidermal growth factor receptor and vascular endothelial growth factor. Strategies to conjugate mAbs to toxins, radioactive isotopes and chemotherapeutic drugs to improve efficacy are under intense investigation and numerous immunoconjugates have been studied in the clinical setting. However, the molecules have limitations, and so nanomaterials (NMs), which potentially offer more flexibility of design and functionality in providing platforms for binding of multiple therapeutic agents in a single structure, are being examined as an alternative. Studies utilizing mAb-targeted NMs have shown that they exhibit focused targeting, improved pharmacokinetics and improved "passive" drug delivery via leaky vasculature. Nevertheless, before they can be utilized to treat cancer, potential NM toxicity must be thoroughly investigated. Thus, rigorous testing of NM-mAb conjugates in both in vitro and in vivo systems is underway to determine how NM-mAb conjugates will interact with cells and tissues of the body. In this review, we discuss the broad range of nanomaterials that are under investigation as potential platforms for the presentation of mAbs either as single therapeutics or in combination with other drugs and their advantages and limitations in specifically targeting cancer.
引用
收藏
页码:467 / 478
页数:12
相关论文
共 50 条
  • [21] Antibody-targeted nanoparticles for cancer treatment (vol 8, pg 941, 2016)
    Carter, Thomas
    Mulholland, Paul
    Chester, Kerry
    Immunotherapy, 2016, 8 (09) : 1151 - 1151
  • [22] Monoclonal antibody drug immunoconjugates for targeted treatment of cancer
    Pamela A. Trail
    Dalton H. King
    Gene M. Dubowchik
    Cancer Immunology, Immunotherapy, 2003, 52 : 328 - 337
  • [23] MALIGNANT ASCITES - REVIEW OF THE LITERATURE, AND AN UPDATE ON MONOCLONAL ANTIBODY-TARGETED THERAPY
    HIRD, V
    THOMAS, H
    STEWART, JSW
    EPENETOS, AA
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1989, 32 (01) : 37 - 45
  • [24] INVITRO COMPARISONS BETWEEN MONOCLONAL ANTIBODY-TARGETED DRUG AND TOXIN CONJUGATES
    EMBLETON, MJ
    BYERS, VS
    GARNETT, MC
    BALDWIN, RW
    BRITISH JOURNAL OF CANCER, 1985, 52 (03) : 432 - 432
  • [25] Monoclonal antibody drug immunoconjugates for targeted treatment of cancer
    Trail, PA
    King, HD
    Dubowchik, GM
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (05) : 328 - 337
  • [26] ANTIBODY-TARGETED PHOTODYNAMIC THERAPY
    SCHMIDT, S
    HYBRIDOMA, 1993, 12 (05): : 539 - 541
  • [27] ANTIBODY-TARGETED CYCLOSPORINE-A
    RIHOVA, B
    JEGOROV, A
    STROHALM, J
    MATHA, V
    ROSSMANN, P
    FORNUSEK, L
    ULBRICH, K
    JOURNAL OF CONTROLLED RELEASE, 1992, 19 (1-3) : 25 - 39
  • [28] ANTIBODY-TARGETED LEUCINOSTATIN-A
    DOSIO, F
    RICCI, M
    BRUSA, P
    ROSSI, C
    CATTEL, L
    JOURNAL OF CONTROLLED RELEASE, 1994, 32 (01) : 37 - 44
  • [29] Development of antibody-targeted vaccines
    Keler, T
    He, LZ
    Graziano, RF
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2005, 7 (02) : 157 - 163
  • [30] Antibody-targeted photodynamic therapy
    Mayo, GL
    Melendez, RF
    Kumar, N
    McKinnon, SJ
    Glickman, RD
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 136 (06) : 1151 - 1152